No connection

Search Results

ARCT vs KPTI

ARCT
Arcturus Therapeutics Holdings Inc.
BEARISH
Price
$6.68
Market Cap
$189.9M
Sector
Healthcare
AI Confidence
85%
KPTI
Karyopharm Therapeutics Inc.
BEARISH
Price
$8.00
Market Cap
$180.3M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
ARCT
--
KPTI
--
Forward P/E
ARCT
-1.61
KPTI
-1.83
P/B Ratio
ARCT
0.89
KPTI
-0.5
P/S Ratio
ARCT
2.31
KPTI
1.23
EV/EBITDA
ARCT
0.22
KPTI
-4.3

Profitability

Gross Margin
ARCT
-36.79%
KPTI
9.93%
Operating Margin
ARCT
-435.06%
KPTI
-52.36%
Profit Margin
ARCT
-80.19%
KPTI
-134.21%
ROE
ARCT
-28.92%
KPTI
--
ROA
ARCT
-15.5%
KPTI
-41.56%

Growth

Revenue Growth
ARCT
-68.4%
KPTI
11.6%
Earnings Growth
ARCT
--
KPTI
--

Financial Health

Debt/Equity
ARCT
0.12
KPTI
--
Current Ratio
ARCT
6.64
KPTI
1.12
Quick Ratio
ARCT
6.5
KPTI
0.98

Dividends

Dividend Yield
ARCT
--
KPTI
--
Payout Ratio
ARCT
0.0%
KPTI
0.0%

AI Verdict

ARCT BEARISH

ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.

Strengths
Analyst consensus is 'buy' with a target price of $23.44, implying significant upside potential
Insider sentiment is moderately positive at 40/100, suggesting some confidence in long-term prospects
Strong liquidity with a current ratio of 6.64 and quick ratio of 6.50, indicating robust short-term financial health
Risks
Piotroski F-Score of 0/9 indicates extreme financial instability and operational failure across all nine criteria
Revenue declined 68.4% YoY, signaling a severe contraction in business activity
Negative profit margins across all measures: -80.19% (net), -435.06% (operating), -36.79% (gross)
KPTI BEARISH

KPTI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.50, indicating negative shareholder equity. While the stock has seen a speculative 1-year price surge of 100.5%, the underlying fundamentals are catastrophic with a profit margin of -134.21% and a consistent track record of missing earnings estimates (0/4 in the last year). Despite bullish analyst targets, the combination of insider selling and extreme operational inefficiency suggests a high risk of further capital erosion.

Strengths
Positive year-over-year revenue growth of 11.60%
Recent 1-year price recovery (+100.5%)
Improving EPS growth trend (+38.1% YoY), though still deeply negative
Risks
Negative Book Value (P/B -0.50) indicating insolvency risk
Extreme operational losses (Profit Margin -134.21%)
Critical Piotroski F-Score (1/9) signaling fundamental weakness

Compare Another Pair

ARCT vs KPTI: Head-to-Head Comparison

This page compares Arcturus Therapeutics Holdings Inc. (ARCT) and Karyopharm Therapeutics Inc. (KPTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile